Significance of MYCN amplification in international neuroblastoma staging systEm stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 365-370

  Bagatell, Rochelle ^a   Beck Popovic, Maja ^a   London, Wendy B ^a   Zhang, Yang ^a   Pearson, Andrew D J ^a   Matthay, Katherine K ^a   Monclair, Tom ^a   Ambros, Peter F ^a   Cohn, Susan L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIPLOIDY; EVENT FREE SURVIVAL; GENE AMPLIFICATION; HUMAN; NEUROBLASTOMA; ONCOGENE; ONCOGENE MYCN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DIPLOIDY; DISEASE-FREE SURVIVAL; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EID: 58749083347     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.9184     Document Type: Article

References (23)

1. Strother D, London WB, Yap J, et al: Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: Preliminary results of Children's Oncology Group protocol 9641. International Society of Paediatric Oncology (SIOP) XXXVIII Congress Meeting, Geneva, Switzerland, September 17-21, 2006
2. Matthay KK, Sather HN, Seeger RC, et al: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 7:236-244, 1989
3. Kushner BH, Cheung NK, LaQuaglia MP, et al: International neuroblastoma staging system stage 1 neuroblastoma: A prospective study and literature review. J Clin Oncol 14:2174-2180, 1996
4. Evans AE, Silber JH, Shpilsky A, et al: Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 14:2504-2510, 1996
5. Berthold F, Treuner J, Brandeis WE, et al: Neuroblastoma study NBL 79 of the German Society for Pediatric Oncology: Report after 2 years [in German]. Klinische Padiatrie 194:262-269, 1982
6. Cohn SL, Look AT, Joshi VV, et al: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study. Cancer Res 55:721-726, 1995
7. Alvarado CS, London WB, Look AT, et al: Natural history and biology of stage A neuroblas-toma: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 22:197-205, 2000
8. Perez CA, Matthay KK, Atkinson JB, et al: Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study. J Clin Oncol 18:18-26, 2000
9. George RE, Variend S, Cullinane C, et al: Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study United Kingdom Children Cancer Study Group. Med Pediat Oncol 36:169-176, 2001
10. Cohn SL, Pearson ADJ, London WB, et al: International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force report. J Clin Oncol doi:10.1200/JCO.2008.16.6785 [epub ahead of print on December 1, 2008]
11. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuro-blastomas correlates with advanced disease stage. Science 224:1 121-1 124, 1984
12. Christiansen H, Delattre O, Fuchs S, et al: Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: Results of the German Neuroblastoma Study Group. Prog Clin Biol Res 385:19-25, 1994
13. Wada RK, Seeger RC, Brodeur GM, et al: Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res 271:57-69, 1988
14. Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N-myc gene amplification by fluores-cence in situ hybridization: Diagnostic utility for neuro-blastoma. American J Pathol 142:1339-1346, 1993
15. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblas-toma and an age-linked classification of neuroblas-tomas. J Natl Cancer Inst 73:405-416, 1984
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J American Statistical Association 53:457-481, 1958
17. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. JRSSA 135:185-198, 1972
18. Attiyeh EF, London WB, Mosse YP, et al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253, 2005
19. Schneiderman J, London WB, Brodeur GM, et al: Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: A report from the Childrens Oncology Group. J Clin Oncol 26:913-918, 2008
20. Ambros IM, Benard J, Boavida M, et al: Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21:2077-2084, 2003
21. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblas-toma. J Clin Oncol 6:1874-1881, 1988
22. CastleberryRP, Pritchard J, AmbrosP, etal: The International Neuroblastoma Risk Groups (INRG): A preliminary report. Eur J Cancer 33:2113-2116, 1997
23. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999